New combo therapy aims to stop daytime accidents in kids
NCT ID NCT06551246
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a combination of two drugs (solifenacin and mirabegron) at low doses works better than a high dose of either drug alone for children aged 5 to 14 with daytime wetting. About 236 children who did not fully respond to low-dose single drugs will be randomly assigned to one of four treatment groups for 18 weeks. The goal is to reduce the number of wet days per week.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 236 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 to 14 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation of any study specific procedures. 2. Age 5 to 14 years (inclusive) at the time of inclusion. 3. Overactive bladder as per International Children's Continence Society criteria 4. At least 2 daytime urinary incontinence episodes per week 5. Inadequate effect of at least 4 weeks urotherapy (non-pharmacological treatment) 6. No previous treatment with solifenacin, mirabegron or bladder/sphincter botulinum toxin injections 7. No current constipation as per ROME IV criteria or fecal incontinence (laxative treatment is accepted) 8. Per investigator's judgment, the participant can swallow or can learn to swallow study medication Exclusion Criteria: 1. Inability of the patent(s) or legal guardian(s) to understand the Danish written and oral information 2. Known or suspected hypersensitivity to study medication 3. Any contraindication to the use of the study medication 4. Known urogenital anatomical abnormalities affecting lower urinary tract function 5. Known kidney or bladder stones 6. Known diabetes insipidus 7. Ongoing symptomatic urinary tract infection 8. Recurrent urinary tract infection or ongoing prophylactic antibiotic treatment 9. Known QTc prolongation, QTc \>460 ms, or risk of QTc prolongation (hypokalaemia, exercise-induced syncope, or familial long QT syndrome) 10. Other significant electrocardiogram abnormalities 11. Known hypertension 12. ≤3 daily voiding, evaluated by 48-hour frequency-volume chart 13. Uroflowmetry suggestive of other pathology than overactive bladder (staccato-shaped, interrupted-shaped, or plateau-shaped curve) 14. Post-void residual \>50 ml after double voiding 15. Dipstick haematuria (≥2+ erythrocytes) or macroscopic haematuria 16. Pregnancy or breastfeeding 17. Female subjects of childbearing potential 18. Ongoing constipation according to Rome IV-criteria which is intractable to medication or fecal incontinence 19. Inability to swallow study medication 20. Use of any medication during study period, except permitted medication
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Urinary incontinence in children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Pediatric and Adolescent Medicine, Aalborg University Hospital
RECRUITINGAalborg, Aalborg, 9000, Denmark
-
Department of Pediatric and Adolescent Medicine, Aarhus University Hospital
RECRUITINGAarhus, Aarhus N, 8200, Denmark
-
Department of Pediatric and Adolescent Medicine, Gødstrup Hospital
RECRUITINGHerning, Herning, 7400, Denmark
-
Department of Pediatric and Adolescent Medicine, Kolding Hospital
RECRUITINGKolding, Kolding, 6000, Denmark
-
Department of Pediatric and Adolescent medicine, Esbjerg Hospital
RECRUITINGEsbjerg, Esbjerg, 6700, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.